Alzheimer's medication where does it occure ?

The development of the next generation of Alzheimer's disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the congress is to bring together today's worldwide leaders in the treatment of Alzheimer's disease in order to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer's disease treatments. The CTAD Congress participants will be able to share their experience on Alzheimer's disease treatments and dementia symptoms. The CTAD 2019 Congress will provide the participants with new reports on the biomarkers from the clinical trial teams. The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2018 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease symptoms or even at the asymptomatic stage. The CTAD 2019 Congress will highlight the latest on trying to get these trials off the ground. Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments. Reviews, original research articles and short reports on Alzheimer prevention will be published in the JPAD . They will include articles on the following topics : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.